Navigating the Path to Managed Formularies

As chronic disease and specialty drugs steadily claim a higher proportion of drug-benefit costs, the move to managed private drug plans appears inevitable. Yet how do we choose which drugs to cover? Is the less expensive medication necessarily the most cost-effective? How do we capture the relative value of a drug in terms of its impact on absenteeism and productivity? Industry leaders explored these and other questions as participants in the 2012 Canadian Leadership Council on Drug Evaluation, which met formally in June.

Read the highlights in the downloadable report (also published in the September issue of Benefits Canada), and listen to key messages presented by this year’s guest speakers.

The Canadian Leadership Council on Drug Evaluation would not have been possible without the support of our sponsors: Amgen, AstraZeneca, Bristol-Myers Squibb Canada, Eli Lilly Canada, Merck Canada Inc., and Novartis Pharmaceuticals Canada Inc.